<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123704</url>
  </required_header>
  <id_info>
    <org_study_id>H-43432</org_study_id>
    <nct_id>NCT04123704</nct_id>
  </id_info>
  <brief_title>Sitravatinib in Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maryam Nemati Shafaee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of sitravatinib in patients with metastatic breast cancer.
      All study participants will receive sitravatinib, 120 mg daily, until their cancer worsens,
      or until they develop intolerable side effects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical Benefit Rate is defined as Objective Response Rate (ORR) plus Stable Disease (SD) for 24 weeks as per Response Evaluation Criteria In Solid Tumours (RECIST) v1.1. ORR is defined Complete Response plus Partial Response per RECIST v1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to progression is calculated from Day 1 of sitravatinib therapy to first evidence of disease progression, as determine by Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Grade 3 or higher adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer Stage IV</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Sitravatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitravatinib 120 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>sitravatinib capsule</description>
    <arm_group_label>Sitravatinib</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women or men age 18 and older

          -  Metastatic or locally advanced inoperable disease breast cancer

          -  Tumor is estrogen receptor (ER) negative and progesterone receptor (PR) negative per
             the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)
             Guidelines of 2010.

          -  Tumor is HER2neu negative per ASCO/CAP Guidelines of 2018

          -  Patient has tumor tissue blocks from metastatic or locally advanced breast cancer
             (beyond curative management) for the analysis of PTPN12 status

          -  Metastatic disease or locally advanced breast cancer (beyond curative management) that
             is measurable according to RECIST 1.1 criteria. Patients with bone only disease are
             eligible for enrollment if there is at least one lytic lesion that can be followed for
             response.

          -  At least one prior line of chemotherapy with or without a PDL1 or PD1 antibody in
             metastatic setting

          -  Patient has Eastern Cooperative Oncology Group (ECOG) performance status &lt;2 (Karnofsky
             &gt; 60%)

          -  Patients must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count &gt; 1000/mcL

               -  Hemoglobin &gt; 11 g/dL

               -  Platelets &gt;100,000/mcL

               -  Total bilirubin &lt; 1.5 X normal institutional limits

               -  Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) &lt; 2.5 X
                  institutional upper limit of normal (ULN) or ≤ 5.0 × ULN for patients with
                  documented liver metastases.

               -  Creatinine within normal institutional limits

               -  Creatinine clearance &gt; 30 mL/min/1.73 m2

               -  Normal left ventricular ejection (LVEF) function defined as normal left
                  ventricular wall motion and ejection fraction of ≥ 50%.

          -  If patient has brain metastasis, documented treatment and stability for at least 30
             days by scans and off steroids at the time of enrollment

          -  Women of child bearing age and actively menstruating must have a negative pregnancy
             test prior to study enrollment.

          -  Ability to understand and the willingness to give informed consent

        Exclusion Criteria:

          -  Untreated hypertension defined as systolic blood pressure &gt; 140 and/or diastolic blood
             pressure &gt; 90 on two or more occasions within the past 30 days previous to enrollment

          -  Imaging suggestive of Lymphangitic carcinomatosis in the lung, or use of home oxygen

          -  Untreated brain metastases.

          -  Pregnancy or lactation at time of trial enrollment

          -  Concomitant metastatic disease of another tumor type

          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of the study drugs

          -  History of stroke, pulmonary embolus (PE), or myocardial infarction (MI) at any time

          -  Known Proteinuria of ≥ 2 g/24 h

          -  HIV-positive participants.

          -  History of Hepatitis C and Hepatitis B infection

          -  Documented history of congestive heart failure, and/or LVEF less than 50%

          -  Concurrent use of medications on the prohibited medications list, unless these
             medications can be replaced by alternatives. These medications need to be discontinued
             at least 2 weeks prior to enrollment.

          -  Presence of other medical condition that, in the sole judgment of the principal
             investigator, makes the patient not a good candidate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Pavlick, BS</last_name>
    <phone>713-798-7814</phone>
    <email>clinical-research@breastcenter.tmc.edu</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Breast Care Center</investigator_affiliation>
    <investigator_full_name>Maryam Nemati Shafaee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>triple negative</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>sitravatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

